follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Moorestown biotech company uses crowdfunding to develop autoimmune diseases treatment drugs

By

Back to Top Comments Print

Latest News

advertisement

Atlantic Bio Sci LLC, a Moorestown-based biotechnology company startup, is developing new oral drugs for the treatment of autoimmune diseases.

According to a press release, the company has started a 'Help Control Autoimmune Disease Now" crowdfunding project through MedStartr. The project will fund further development of the potential drug (ABS11) in preclinical studies of autoimmune diseases chosen from Type 1 diabetes, psoriasis, rheumatoid arthritis/juvenile arthritis, multiple sclerosis, lupus and colitis.

Raising additional funds more than the $10,000 goal moves Altantic Bio Sci closer to testing ABS11 in clinical trials in patients with autoimmune diseases. Contributions of any amount allow backers to vote for the autoimmune disease they choose to be tested in the next Atlantic Bio Sci study, the release said.

"Atlantic Bio Sci, LLC has a multifaceted approach to fundraising and we have chosen to start by taking the funding need directly to the public, including autoimmune disease patients and their loved ones, who will ultimately benefit from the work of Atlantic Bio Sci, LLC," the company said.

ALSO ON NJBIZ:

Getting canned: Why beer tastes better, sells better in cans

Poll: Christie job approval rating down 20 points from past year

Cassidy Turley to list Woodmont's I-78 Logistics Center in Clinton

Emily Bader

Emily Bader

Emily Bader is the copy and web editor at NJBIZ. She is a Brielle, N.J. native and a Rutgers University alum. You can contact her at emilyb@njbiz.com or @emilybader on Twitter.

advertisement

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top